Becker's Healthcare September 18, 2024
GLP-1 weight loss medications like Ozempic and Wegovy have become blockbuster drugs, but the need for weekly injections has limited their use. This may soon change, as several oral versions are nearing FDA approval, CNN reported Sept. 17.
Semaglutide, the active ingredient in Ozempic, is being developed in pill form by Novo Nordisk and has shown promising results, with study participants losing an average of 15% of their body weight over 68 weeks.
Other pharmaceutical companies are also entering the race to develop oral GLP-1 treatments. Eli Lilly...
Today's Sponsors
Today's Sponsor